Drug Profile

ONC 783

Alternative Names: ONC-783

Latest Information Update: 19 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator OncoC4
Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours
Preclinical Haematological malignancies

Most Recent Events

17 Aug 2026 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (SC) (NCT07408258)
17 Aug 2026 The US FDA approves IND application for ONC 783 in Solid tumours
17 Aug 2026 Adverse events data from a phase I trial in Solid tumours released by OncoC4

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com